Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

David Gonzalez-Martinez, L. E. Roth, Thomas R. Mumford, Juan Guan, Anh‐Tuan Le, Robert C. Doebele, Bo Huang, Asmin Tulpule, Magdalena Niewiadomska-Bugaj, Trever G. Bivona, Lukasz J. BugajNature Communications 2024 · DOI

Abstract

Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene and adapter protein multimers. While these assemblies are associated with oncogenic signaling, their role in drug response is unclear. Here, we use optogenetics and live-cell imaging to find that EML4-ALK assemblies suppress transmembrane receptor tyrosine kinase (RTK) signaling by sequestering RTK adapter proteins including GRB2 and SOS1. Furthermore, ALK inhibition, while suppressing oncogenic signaling, simultaneously releases the sequestered adapters and thereby resensitizes RTK signaling. Resensitized RTKs promote rapid and pulsatile ERK reactivation that originates from paracrine ligands shed by dying cells. Reactivated ERK signaling promotes cell survival, which can be counteracted by combination therapies that block paracrine signaling. Our results identify a regulatory role for RTK fusion assemblies and uncover a mechanism of tolerance to targeted therapies.

Introduction

Lung cancers driven by the EML4-ALK fusion protein often exhibit initial sensitivity to ALK inhibitors (ALKi), yet frequently progress to a state of drug tolerance. This "persistence" allows a subset of cells to survive treatment and eventually develop stable resistance. A defining physical characteristic of EML4-ALK is its tendency to form cytoplasmic protein condensates—membraneless droplets that serve as active signaling hubs. This study investigates how these spatial assemblies influence a cancer cell's perception of its environment and contribute to therapeutic evasion.

The "Molecular Sponge" Mechanism

The researchers discovered that EML4-ALK condensates act as "molecular sponges," sequestering essential signaling adapters such as GRB2 and SOS1. By physically trapping these proteins, the oncogenic clusters effectively "blind" the cell to external growth factors by depleting the pool of adapters available to surface receptor tyrosine kinases (RTKs).

EML4-ALK clusters sequester RTK adapters, modulating oncogenic signaling and drug tolerance.

Methods and Experimental Design

To probe these pathways with high precision, the team utilized:

  • Optogenetic Functional Profiling: Light-activated proteins (optoFGFR and optoSOS) were used to trigger specific nodes of the signaling pathway with blue light, allowing for precise control over signal timing and intensity.
  • Live-Cell Biosensors: The ErkKTR fluorescent reporter provided real-time tracking of ERK activity at the single-cell level.
  • Cell Models: Experiments were conducted in established NSCLC cell lines (STE-1, H3122), patient-derived lines (CUTO-8, CUTO-9), and non-cancerous lung epithelial models (Beas2B).

Key Results: Resensitization and Paracrine Survival

A paradoxical effect occurs upon treatment with ALK inhibitors: as the oncogenic signaling is suppressed, the condensates release the sequestered adapters back into the cytoplasm. This rapid release (half-life of ~17 minutes) "resensitizes" the cell to its environment precisely when the drug is most active.

Optogenetic profiling demonstrates that ALK inhibition sensitizes the RTK response in EML4-ALK+ cells.

The study found that ALKi treatment increased the dynamic range of the response to external growth factors like EGF by approximately 10-fold. Furthermore, as cells begin to die from the treatment, they release paracrine signals (growth factors) that are picked up by their newly resensitized neighbors. This "death-induced survival" leads to pulsatile ERK reactivation in surviving cells, promoting persistence.

Conclusion and Therapeutic Implications

The findings suggest that the spatial organization of oncogenes plays a critical regulatory role in drug response. This mechanism is not limited to ALK; similar sequestration was observed in RET-fusion models. Importantly, the study demonstrated that combining ALK inhibitors with drugs that block these rescue signals (e.g., EGFR or MMP inhibitors) significantly reduced the population of persister cells. Future research will explore whether similar "molecular sinks" exist in other diseases characterized by protein aggregation.

Summary updated

Abstract

Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene and adapter protein multimers. While these assemblies are associated with oncogenic signaling, their role in drug response is unclear. Here, we use optogenetics and live-cell imaging to find that EML4-ALK assemblies suppress transmembrane receptor tyrosine kinase (RTK) signaling by sequestering RTK adapter proteins including GRB2 and SOS1. Furthermore, ALK inhibition, while suppressing oncogenic signaling, simultaneously releases the sequestered adapters and thereby resensitizes RTK signaling. Resensitized RTKs promote rapid and pulsatile ERK reactivation that originates from paracrine ligands shed by dying cells. Reactivated ERK signaling promotes cell survival, which can be counteracted by combination therapies that block paracrine signaling. Our results identify a regulatory role for RTK fusion assemblies and uncover a mechanism of tolerance to targeted therapies.
BibTeX
@inproceedings{gonzalezmartinez2024oncogenic,
  author = {David Gonzalez-Martinez and L. E. Roth and Thomas R. Mumford and Juan Guan and Anh‐Tuan Le and Robert C. Doebele and Bo Huang and Asmin Tulpule and Magdalena Niewiadomska-Bugaj and Trever G. Bivona and Lukasz J. Bugaj},
  title = {{Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-53451-7},
}
Figure